Please assess the completion status of the following clinical trial:

Trial Title: Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Male and female subjects ≥18 years of age with newly diagnosed advanced stage RCC will be eligible for inclusion in this study if all of the following criteria apply:~1. Newly diagnosed advanced stage RCC.~2. Eligible for unilateral nephrectomy or partial nephrectomy; OR, Has lesion accessible for excisional biopsy/metastasectomy.~3. Measurable disease.~4. Candidate for sunitinib treatment as labeled.~5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~6. Memorial Sloan Kettering Cancer Center (MSKCC) risk group 0 or 1.~7. No brain metastases detected by MRI.~8. Normal renal function in the contralateral kidney.~9. Able to abstain from taking prohibited prescription or prohibited non-prescription drugs.~10. Use of appropriate birth control methods for the duration of the study for women of childbearing potential and men with female partners of childbearing potential.~11. Clinically acceptable Screening results according to the following specific limits:~    * Adequate hematologic function.~   * Adequate renal and hepatic function.~   * Adequate coagulation function.~12. Normal serum calcium.~13. Ability to communicate effectively with study personnel; considered reliable, willing, and cooperative in terms of compliance with the Protocol requirements.~14. Voluntary informed consent given to participate in the study.~Exclusion Criteria:~Subjects will NOT be eligible for inclusion in this study if any of the following criteria apply:~1. Nephrectomy for RCC therapy is required.~2. Any serious medical condition or illness considered by the investigator to constitute an unwarranted high risk for investigational treatment.~3. Uncontrolled hypertension.~4. Type I diabetes mellitus (insulin therapy for Type II diabetes IS permitted).~5. Prior systemic therapy for advanced stage RCC.~6. Active autoimmune disease.~7. Prior history of malignancy other than RCC within the preceding 5 years, except for adequately treated cervical cancer or non-melanoma skin cancer.~8. Use of prohibited prescription or prohibited non-prescription drugs during 2 months prior to entry into the study.~9. Active, acute, or chronic clinically significant infections.~10. Use of another investigational drug or participation in any investigational drug study within the 28 days prior to the start of study enrollment.~11. Planned or elective anti-cancer surgical treatment other than nephrectomy/excisional biopsy/metastasectomy.~12. History of hypercalcemia, symptomatic hypercalcemia, or hypercalcemia requiring management.~13. Known hypersensitivity to dimethyl sulfoxide (DMSO).~14. Body weight less than 30 kg.~15. Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1: AGS-003+sunitinib (Type: EXPERIMENTAL): Single arm study AGS-003 plus sunitinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete